New hope for rare blood cancers: pacritinib trial opens for teens and adults

NCT ID NCT06303193

Recruiting now Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 34 times

Summary

This study tests an oral drug called pacritinib in people aged 12 and older with myelodysplastic syndromes (MDS) or related blood cancers (MDS/MPN). The goal is to find the best dose and see if it can shrink or control the disease. Participants take capsules twice daily for up to 8 years, with regular checkups and bone marrow biopsies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pacritinib
What this could lead to: If successful, this could provide a new oral treatment option for people with MDS or MDS/MPN, potentially controlling the disease and delaying progression.
What could go wrong: This is an early-phase trial with a small number of participants, so the drug may not work as hoped or could cause unexpected side effects. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

aplastic anemia bone marrow disorder myelodysplastic syndrome myelodysplastic syndrome with excess blasts Myelodysplastic Syndromes myelodysplastic/myeloproliferative neoplasm Myeloproliferative Disorders

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELODYSPLASTIC SYNDROMES

Contacts and locations

Locations

National Institutes of Health Clinical Center
RECRUITING

Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.